Page last updated: 2024-12-08
dacuronium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dacuronium: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 218421 |
| CHEMBL ID | 3138543 |
| MeSH ID | M0044587 |
Synonyms (14)
| Synonym |
|---|
| dacuronium |
| 43021-45-0 |
| [(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-17-hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate |
| 17-hydroxypancuronium |
| piperidinium, 3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis-(1-methyl- |
| vd6l56zvx1 , |
| unii-vd6l56zvx1 |
| dacuronium ion |
| 3.alpha.,17.beta.-dihydroxy-5.alpha.-androstan-2.beta.,16.beta.-ylene)bis-(1-methylpiperidinium) 3-acetate |
| dacuronium cation |
| CHEMBL3138543 |
| Q27291768 |
| 1,1'-((2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-acetoxy-17-hydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthrene-2,16-diyl)bis(1-methylpiperidin-1-ium) |
| AKOS040745721 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "To compare two oral contraceptive pills, both containing 150 micrograms desogestrel, but with either 20 micrograms (Mercilon) or 30 micrograms (Marvelon/Desolett) ethinyl oestradiol (EE), regarding reliability, cycle control and side effect profile." | ( Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Akerlund, M; Røde, A; Westergaard, J, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.09) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 8 (47.06%) | 5.53% |
| Reviews | 2 (11.76%) | 6.00% |
| Case Studies | 1 (5.88%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (35.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Pain Relief and Inflammatory Status in Women With Surgically Confirmed Endometriosis Treated With Atorvastatin, Oral Contraceptive or Combined Oral Contraceptives and Atorvastatin: Open Randomized Controlled Trial [NCT00675779] | 44 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| Open, Randomized, Parallel Multi-center Comparison of Cycle Control and Safety of the Oral Contraceptive Yasmin 20 in a 24-day Regimen vs. Mercilon for 7 Cycles in 440 Healthy Female Volunteers [NCT00624130] | Phase 3 | 453 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||